NLRP3 and metabolic dysfunction-associated steatotic liver disease: In non-alcoholic fatty liver disease (NAFLD) models, mangiferin (47) mitigated liver injury, insulin resistance, and glucose intolerance by modulating glucolipid metabolism through AMPK activation and NLRP3 inflammasome inhibition [60].